Abstract

LifeStance Health Group, Inc. will report quarterly results on May 7, 2026 Pre-Market; investors are watching revenue growth, margin trajectory, and earnings leverage as consensus points to a modest profit and mid-teens top-line expansion.

Market Forecast

Market expectations point to LifeStance Health Group, Inc. delivering approximately US dollars 387.37 million in revenue for the upcoming quarter, representing 16.36% year-over-year growth, alongside forecast EPS of US dollars 0.007 and EBIT of US dollars 10.05 million; year-over-year changes implied by these forecasts are 120.52% for EPS and 288.92% for EBIT. The company has not provided explicit guidance for current-quarter gross profit margin or net profit margin in the available forecast data; however, investors will be monitoring whether margins track or improve from last quarter’s levels.

Patient services remain the core revenue engine, benefiting from utilization improvements and steady demand across visit modalities, with an outlook centered on throughput and scheduling efficiency gains that can translate into incremental margin expansion. Within the service mix, virtual and hybrid visits embedded in patient services appear most scalable near term, supported by operational enhancements; momentum here is expected to mirror companywide growth, where revenue rose 17.43% year over year in the prior quarter and is forecast to rise 16.36% this quarter.

Last Quarter Review

In the previous quarter, LifeStance Health Group, Inc. recorded revenue of US dollars 382.20 million (up 17.43% year over year), a gross profit margin of 33.04%, GAAP net profit attributable to the company of US dollars 11.67 million, a net profit margin of 3.05%, and adjusted EPS of US dollars 0.03 (up 250% year over year). Operating income benefited from scale and utilization, with EBIT reaching US dollars 18.08 million, outpacing top-line growth and highlighting early operating leverage.

Patient services dominated the business mix at roughly 99.25% of revenue, equating to about US dollars 379.34 million of the quarter’s total, while non-patient services contributed approximately US dollars 2.86 million; revenue growth was concentrated in core clinical services, which tracked closely with the company’s 17.43% year-over-year revenue increase.

Current Quarter Outlook

Main business performance: patient services and earnings leverage

Patient services are expected to drive the quarter, with management and the market framework pointing to revenue of about US dollars 387.37 million and a return to a small profit per share (forecast EPS of US dollars 0.007). The central question for investors is whether the company can convert mid-teens revenue growth into sequential margin gains after last quarter’s gross margin of 33.04% and net margin of 3.05%. With EBIT forecast at US dollars 10.05 million this quarter, the setup suggests continued operating leverage, provided staffing productivity, visit volumes, and no-show rates remain well managed. Efficiency in scheduling and throughput can widen the gap between revenue and operating expense growth, strengthening incremental margins. Any sustained improvement in clinician utilization should support gross margin resilience and help lift net margin from the low single digits.

The patient services mix remains supportive of revenue visibility as recurring visit volumes and payer relationships underpin demand; this allows the company to focus on improving unit economics rather than relying solely on volume expansion. The prior quarter’s revenue and EBIT dynamics highlighted this leverage potential, and the forecasted 16.36% year-over-year revenue increase, together with a projected positive EPS, indicates progress toward more consistent profitability. Investors will be watching whether visit growth continues at a pace that matches or exceeds staffing ramp targets, as this is a decisive factor for sustaining and expanding margins through the rest of the year.

Most promising business: virtual and hybrid care within patient services

Within patient services, virtual and hybrid care represent the most scalable growth lane in the near term because they integrate with existing clinical workflows and can add incremental capacity without the same fixed-cost intensity as purely in-person expansions. Based on last quarter’s business mix, virtual and hybrid visits are embedded within the approximately US dollars 379.34 million patient services revenue base, with underlying growth likely tracking close to the company’s overall 17.43% year-over-year pace given similar demand drivers. The combination of easier capacity flex, lower incremental costs per encounter, and improved patient access positions this modality to continue gaining share of total visits.

This quarter, the key to unlocking more contribution from this segment is better appointment density and reduction in idle clinician time, both of which are sensitive to technology-enabled scheduling and reminders. If throughput improvements continue, the company can generate more revenue per clinician hour and reduce the effective cost per visit, supporting both gross margin stability and incremental expansion. A measured shift in payer mix toward contracts that reimburse efficiently for virtual services would amplify this effect, raising the likelihood that incremental revenue translates into EBIT in line with or better than last quarter’s conversion.

Key stock price drivers this quarter

Three operational and financial markers are likely to exert the greatest influence on the stock this quarter: revenue growth cadence versus the 16.36% year-over-year forecast, margin trajectory relative to last quarter’s 33.04% gross margin and 3.05% net margin, and confirmation that adjusted EPS turns positive with a path to sustained profitability. If reported revenue aligns with the approximately US dollars 387.37 million projection and management demonstrates incremental margin capture, investors will likely credit the company with improving fundamentals and better earnings power into the second half of the year. Conversely, any disruption in visit volumes, clinician supply, or reimbursement that pressures margins would challenge the positive EPS narrative and could weigh on sentiment.

EBIT delivery versus the US dollars 10.05 million forecast is a practical litmus test for operating leverage. Solid execution here would underscore that last quarter’s EBIT outperformance was not an isolated event. In addition, commentary around staffing, clinic-level utilization, and digital scheduling effectiveness will be closely scrutinized as real-time indicators of whether growth can be achieved without proportionate increases in operating expense. Taken together, these factors shape the near-term valuation corridor by clarifying how quickly mid-teens top-line growth can compound into a more durable margin profile.

Analyst Opinions

Across the period from January 1, 2026 to April 30, 2026, tracked views are decisively bullish, with four bullish opinions and zero bearish opinions, indicating a 100% favorable skew. UBS raised its price target to US dollars 12 from US dollars 10 while maintaining a Buy rating, citing confidence in the company’s growth trajectory and improving financial profile as management guides toward continued top-line expansion. Morgan Stanley reiterated a Buy rating with a US dollars 10 price target, referencing improving utilization, stronger fundamentals, and technology-driven growth as core tenets of its constructive stance. Barclays maintained a Buy rating with a US dollars 9 price target, highlighting a supportive setup into the quarter given progress on operational efficiency and revenue run-rate stability.

These views collectively emphasize that the market is looking for confirmation of sustainable operating leverage rather than outsized top-line surprises. The expectation framework—revenue around US dollars 387.37 million, forecast EPS of US dollars 0.007, and EBIT near US dollars 10.05 million—implies that modest beats on margins or expenses could have a material impact on perceived earnings quality. Analysts point to utilization, throughput, and tech-enabled scheduling as the mechanisms most capable of lifting profitability without sacrificing growth, which aligns with the recent pattern of mid-teens revenue gains and sharply improving EPS on a year-over-year basis. In the absence of contrary signals on margins or clinician availability, the balance of opinion suggests the company is positioned to deliver a constructive print and reinforce the path toward steadier profitability over the coming quarters.